title: The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up.
abstract: OBJECTIVE
  To compare the intermediate-term efficacy of 5-fluorouracil (5-FU) and Mitomycin C (MMC) as adjunctive antimetabolites in neovascular glaucoma (NVG) filtration surgery.
  
  
  METHODS
  Forty consecutive eyes of 40 patients with NVG refractory to medical therapy were randomized to receive antimetabolite-augmented trabeculectomy. Eighteen eyes received postoperative 5-FU (5-FU group) and 22 eyes received intraoperative, low-dose (0.2 mg/ml) MMC for 2 mins (MMC group). The main outcome measure was intraocular pressure (IOP). Surgical success was defined as IOP < 21 mmHg with topical treatment (qualified success) or without topical treatment (complete success). Surgical failure was defined as IOP > or = 21 mmHg, despite postoperative topical treatment, and by postoperative blindness.
  
  
  RESULTS
  The mean follow-up period was 35.8 +/- 22.6 months in the 5-FU group and 18.6 +/- 17.2 months in the MMC group. This difference was not significant. Mean IOP decreased from 40.4 +/- 10.3 mmHg to 14.7 +/- 3.4 mmHg (p < 0.0001) in the 5-FU group and from 42 +/- 11.3 mmHg to 22.9 +/- 13.3 mmHg (p = 0.0006) in the MMC group; however, the difference between the 5-FU and MMC groups was not significant at any point. The success rate in the 5-FU group was 55.5% (44.4% complete, 11.1% qualified), compared with 54.5% (9.1% complete, 45.4% qualified) in the MMC group. This difference was not significant.
  
  
  CONCLUSIONS
  The percentage of patients who achieved postoperative IOP < 21 mmHg was similar in both groups, although a larger proportion of patients treated with MMC-augmented trabeculectomy required topical treatment in comparison with the 5-FU group.
authors.affiliation: Department of Ophthalmology and Otorhinolaryngology, University of Bari, Bari, Italy.
authors.forename: Dario
authors.initials: D
authors.lastname: Sisto
authors.forename: Michele
authors.initials: M
authors.lastname: Vetrugno
authors.forename: Tiziana
authors.initials: T
authors.lastname: Trabucco
authors.forename: Francesco
authors.initials: F
authors.lastname: Cantatore
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ruggeri
authors.forename: Carlo
authors.initials: C
authors.lastname: Sborgia
mesh_terms: D000328:Adult; D000368:Aged; D000963:Antimetabolites / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D011182:Postoperative Care; D014130:Trabeculectomy; D016896:Treatment Outcome
chemical_list: D000963:Antimetabolites; D016685:Mitomycin; D005472:Fluorouracil